Nagar Swati, Radice Casey, Tuohy Robert, Stevens Raymond, Bennyhoff Dale, Korzekwa Ken
Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania19140, United States.
Pace Analytical Life Sciences LLC, Norristown, Pennsylvania19401, United States.
Mol Pharm. 2023 Jan 2;20(1):219-231. doi: 10.1021/acs.molpharmaceut.2c00597. Epub 2022 Dec 21.
Oral drug absorption is known to be impacted by the physicochemical properties of drugs, properties of oral formulations, and physiological characteristics of the intestine. The goal of the present study was to develop a mathematical model to predict the impact of particle size, feeding time, and intestinal transporter activity on oral absorption. A previously published rat continuous intestine absorption model was extended for solid drug absorption. The impact of active pharmaceutical ingredient particle size was evaluated with glyburide (GLY) as a model drug. Two particle size suspensions of glyburide were prepared with average particle sizes of 42.7 and 4.1 μm. Each suspension was dosed as a single oral gavage to male Sprague Dawley rats, and concentration-time (-) profiles of glyburide were measured with liquid chromatography coupled with tandem mass spectrometry. A continuous rat intestine absorption model was extended to include drug dissolution and was used to predict the absorption kinetics of GLY depending on particle size. Additional literature datasets of rat GLY formulations with particle sizes ranging from 0.25 to 4.0 μm were used for model predictions. The model predicted reasonably well the absorption profiles of GLY based on varying particle size and varying feeding time. The model predicted inhibition of intestinal uptake or efflux transporters depending on the datasets. The three datasets used formulations with different excipients, which may impact the transporter activity. Model simulations indicated that the model provides a facile framework to predict the impact of transporter inhibition on drug - profiles. Model simulations can also be conducted to evaluate the impact of an altered intestinal lumen environment. In conclusion, the rat continuous intestine absorption model may provide a useful tool to predict the impact of varying drug formulations on rat oral absorption profiles.
众所周知,口服药物吸收会受到药物的物理化学性质、口服制剂的性质以及肠道生理特征的影响。本研究的目的是建立一个数学模型,以预测粒径、给药时间和肠道转运体活性对口服吸收的影响。将先前发表的大鼠连续肠道吸收模型扩展用于固体药物吸收。以格列本脲(GLY)为模型药物评估活性药物成分粒径的影响。制备了两种格列本脲粒径混悬液,平均粒径分别为42.7和4.1μm。每种混悬液经单次灌胃给予雄性Sprague Dawley大鼠,并采用液相色谱-串联质谱法测定格列本脲的浓度-时间曲线。将大鼠连续肠道吸收模型扩展以纳入药物溶解,并用于预测取决于粒径的GLY吸收动力学。使用粒径范围为0.25至4.0μm的大鼠GLY制剂的其他文献数据集进行模型预测。该模型基于不同的粒径和给药时间,对GLY的吸收曲线进行了较为合理的预测。根据数据集,该模型预测了肠道摄取或外排转运体的抑制情况。所使用的三个数据集采用了不同的辅料配方,这可能会影响转运体活性。模型模拟表明,该模型为预测转运体抑制对药物曲线的影响提供了一个简便的框架。还可以进行模型模拟以评估肠道腔环境改变的影响。总之,大鼠连续肠道吸收模型可能为预测不同药物制剂对大鼠口服吸收曲线的影响提供一个有用的工具。